The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
This study evaluated the effects of naltrexone treatment for adults with mental retardation and self-injury across, a selection of dose levels, target behaviors, subjects and treatment phase durations. Statistical analysis of group results revealed a significant reduction in self-injury rate during naltrexone treatment. However, analysis of single-subject data indicated that only two of the nine subjects assessed demonstrated a significant and maintained suppression of self-injury rate associated with naltrexone treatment. The positive response of these two subjects occurred at the higher naltrexone dose level (100 mg/day) and appeared to be related to increased bioavailability of 6-beta-naltrexol, the active metabolite of naltrexone. Four subjects demonstrated naltrexone-related reductions in stereotypy, and one subject demonstrated naltrexone-related increases in adaptive material interaction. Given the wealth of previous research on naltrexone treatment of self-injury, present findings are discussed in relation to those of previous studies that have found more positive results....